UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

[x]  Quarterly report under Section 13 or 15(d) of the Securities Exchange Act
     of 1934

     For the quarterly period ended September 30, 2005

[ ]  Transition report under Section 13 or 15(d) of the Securities Exchange
     Act of 1934

     For the transition period from ____________ to ____________

                        Commission file number: 001-16133

                              DELCATH SYSTEMS, INC.
        -----------------------------------------------------------------
        (Exact Name of Small Business Issuer as Specified in Its Charter)

                   Delaware                           06-1245881
         -------------------------------         ------------------------
         (State or Other Jurisdiction of           (I.R.S. Employer
          Incorporation or Organization)          Identification No.)

                1100 Summer Street, 3rd Floor, Stamford, CT 06905
              ----------------------------------------------------
                    (Address of Principal Executive Offices)

                                 (203) 323-8668
            --------------------------------------------------------
                (Issuer's Telephone Number, Including Area Code)

                                       N/A
      ---------------------------------------------------------------------
      (Former Name, Former Address and Former Fiscal Year, if Changed Since
                                  Last Report)

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act. Yes [ ] No [X]

As of November 2, 2005, 16,640,896 shares of the Issuer's common stock, $0.01
par value, were issued and outstanding.

Transitional Small Business Disclosure Format (check one): Yes [ ] No [X]





                              DELCATH SYSTEMS, INC.

                                      Index


                                                                        Page No.
                                                                        -------

Part I.  FINANCIAL INFORMATION

Item 1.  Condensed Financial Statements (Unaudited)

Condensed Balance Sheet - September 30, 2005                                3

Condensed Statements of Operations for the Three and Nine Months Ended      4
     September 30, 2005 and 2004 and Cumulative from Inception
     (August 5, 1988) to September 30, 2005

Condensed Statements of Cash Flows for the Nine Months Ended                5
     September 30, 2005 and 2004 and Cumulative from Inception
     (August 5, 1988) to September 30, 2005

Notes to Condensed Financial Statements                                     6

Item 2.  Management's Discussion and Analysis or
         Plan of Operation                                                  9

Item 3.  Controls and Procedures                                           11

Part II. OTHER INFORMATION

Item 1.  Legal Proceedings                                                 12

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds       12

Item 3.  Defaults Upon Senior Securities                                   12

Item 4.  Submission of Matters to a Vote of Security Holders               12

Item 5.  Other Information                                                 12

Item 6.  Exhibits                                                          12

Signatures                                                                 13








                              Delcath Systems, Inc.
                          (A Development Stage Company)
                             Condensed Balance Sheet
                                   (Unaudited)
                               September 30, 2005



                           Assets

Current assets:
     Cash and cash equivalents                              $        862,434 
     Certificates of deposit                                       7,047,077 
     Interest receivable                                             135,804 
     Prepaid insurance                                                 2,170 
                                                              ----------------
                        Total current assets                       8,047,485 

Furniture and fixtures, net                                            9,062 
                                                              ----------------

                        Total assets                        $      8,056,547 
                                                              ================

           Liabilities and Stockholders' Equity

Current liabilities:
     Accounts payable and accrued expenses                  $        222,219 
                                                              ----------------
                        Total current liabilities                    222,219 
                                                              ----------------


Stockholders' equity
     Common stock                                                    166,409
     Additional paid-in capital                                   32,822,631
     Deficit accumulated during development stage                (25,154,712)
                                                              ----------------

                     Total stockholders' equity                    7,834,328 
                                                              ----------------

                     Total liabilities and stockholders'
                        equity                              $      8,056,547 
                                                              ================



See accompanying notes to condensed financial statements


                                       3






                              Delcath Systems, Inc.
                          (A Development Stage Company)
     Condensed Statements of Operations for the Three and Nine Months Ended
   September 30, 2005 and 2004 and Cumulative from Inception (August 5, 1988)
                             to September 30, 2005
                                   (Unaudited)




                                                                                                                      Cumulative
                                                                                                                    From Inception
                                                   Three Months Ended                 Nine Months Ended            (August 5, 1988)
                                                      September 30,                     September 30,                     to
                                                 2005             2004              2005            2004          September 30, 2005
                                      -----------------------------------     -------------------------------    -------------------
                                                                                                             
Costs and expenses:

   General and administrative expense  $         309,820   $      206,975    $     1,017,223         714,263          8,088,084
   Research and development costs                395,332          644,854          1,329,499       1,717,028         16,645,728
                                      ------------------------------------     ------------------------------    -------------------

     Total costs and expenses                    705,152         851,829           2,346,722       2,431,291         24,733,812
                                      ------------------------------------     ------------------------------    -------------------

     Operating loss                             (705,152)       (851,829)         (2,346,722)     (2,431,291)       (24,733,812)

Other income (expense):
   Interest income                                61,399          23,577             162,558          66,880           1,249,178
   Interest expense                                   -               -                   -               -             (171,473)
                                      ------------------------------------     -------------------------------   -------------------

     Net loss                          $        (613,753)       (828,252)         (2,184,164)     (2,364,411)        (23,656,107)
                                      ===================  ===============     =============== ===============   ===================

Common share data:
   Basic and diluted loss
     per share                       $             (0.04)  $       (0.07)        $     (0.14)  $       (0.22)
                                      ===================  ===============     =============== ===============

   Weighted average number
     of shares of common                      16,143,367      11,616,406           5,667,028      10,983,188
                                      ===================  ===============     =============== ===============
     stock outstanding



See accompanying notes to condensed financial statements


                                       4





                              DELCATH SYSTEMS, INC.
                          (A Development Stage Company)

   Condensed Statements of Cash Flows for the Nine Months Ended September 30,
         2005 and 2004 and Cumulative fromInception (August 5, 1988) to
                         September 30, 2005 (Unaudited)



                                                                                 Cumulative
                                                   Nine Months Ended           from inception
                                                    September 30,             (August 5, 1988)
                                                   2005          2004        to September 30, 2005
                                              -----------------------------  --------------------
                                                                                      
Cash flows from operating activities:
   Net loss                                     $ (2,184,164) $ (2,364,411)        $  (23,656,107)
   Adjustments to reconcile net
     loss to net cash used in operating
     activities Stock option expense -
      consultants                                      8,270         5,222             2,533,662
     Stock compensation expense issued to
      management, consultants, and directors
      for services                                   103,425             -               339,711
     Depreciation expense                              4,544         4,012                36,236
     Amortization of organization costs                    -             -                42,165
   Changes in assets and liabilities:
     Decrease in prepaid expenses                     45,646        30,284                (2,170)
     (Increase) in interest receivable              (102,918)      (30,523)             (135,802)
     (Decrease) increase in accounts
      payable and accrued expenses                  (342,407)      213,996               222,218
                                              -----------------------------  --------------------
       Net cash used in operating activities      (2,467,604)   (2,141,420)          (20,620,086)
                                              -----------------------------  --------------------

Cash flows from investing activities:
   Purchase of furniture and fixtures                      -        (5,347)              (45,300)
   Purchase of short-term investments             (3,047,077)   (2,000,000)          (14,016,781)
   Proceeds from maturities of short-term
    investmen                                      3,055,129     1,014,575             6,969,704
   Organization costs                                      -             -               (42,165)
                                              -----------------------------  --------------------
          Net cash provide by (used in)
               investing activities                    8,052      (990,772)           (7,134,542)
                                              -----------------------------  --------------------

Cash flows from financing activities:
   Net proceeds from sale of stock and
     exercise of stock options and warrants        3,119,651     3,739,167            27,462,736
   Repurchases of outstanding common stock                 -             -               (51,103)
   Dividends paid                                          -             -              (499,535)
   Proceeds from short-term borrowings                     -             -             1,704,964
                                              -----------------------------  --------------------
              Net cash provided by
              financing activities                 3,119,651     3,739,167            28,617,062
                                              -----------------------------  --------------------

      Increase in cash and cash equivalents          660,098       606,975               862,434

Cash and cash equivalents at beginning of
 period                                              202,335       313,615                     -
                                              -----------------------------  --------------------

Cash and cash equivalents at end of period         $ 862,434     $ 920,590             $ 862,434
                                              =============================  ====================

   Cash paid for interest                          $       -     $       -             $ 171,473
                                              =============================  ====================

   Supplemental disclosure of non-cash
     activities:
   Conversion of debt to common stock              $       -     $       -            $1,704,964
                                              =============================  ====================
   Common stock issued for preferred stock
    dividends                                      $       -     $       -            $  999,070
                                              =============================  ====================
   Conversion of preferred stock to
    common stock                                   $       -     $       -            $   24,167
                                              =============================  ====================
   Common stock issued as compensation
     for stock sale                                $       -     $       -            $  510,000
                                              =============================  ====================


See accompanying notes to condensed financial statements

                                       5.



                              Delcath Systems, Inc.
                          (A Development Stage Company)

                     Notes to Condensed Financial Statements

Note 1: Description of Business

Delcath Systems, Inc. (the "Company") is a development stage company which was
founded in 1988 for the purpose of developing and marketing a proprietary drug
delivery system capable of introducing, and removing, high dose chemotherapy
agents to a diseased organ while greatly inhibiting their entry into the general
circulation system. It is hoped that the procedure will result in a meaningful
treatment for cancer. In November 1989, the Company was granted an IDE
(Investigational Device Exemption) and an IND (Investigational New Drug) for its
product by the FDA (Food and Drug Administration). The Company is seeking to
complete clinical trials in order to obtain separate FDA pre-market approvals
for the use of its delivery system using doxorubicin and melphalan,
chemotherapeutic agents, to treat malignant melanoma that has spread to the
liver.

Note 2: Basis of Presentation

The accompanying condensed financial statements are unaudited and have been
prepared by the Company in accordance with accounting principles generally
accepted in the United States of America. Certain information and footnote
disclosures normally included in the Company's annual financial statements have
been condensed or omitted. The interim financial statements, in the opinion of
management, reflect all adjustments (consisting of normal recurring accruals)
necessary for a fair statement of the results for the interim periods ended
September 30, 2005 and 2004 and cumulative from inception (August 5, 1988) to
September 30, 2005.

The results of operations for the interim periods are not necessarily indicative
of the results of operations to be expected for the fiscal year. These interim
condensed financial statements should be read in conjunction with the audited
financial statements and notes thereto for the year ended December 31, 2004,
which are contained in the Company's Annual Report on Form 10-KSB for the year
ended December 31, 2004 as filed with the Securities and Exchange Commission.

Note 3: Research and Development Costs

Research and development costs include the costs of materials, personnel,
outside services and applicable indirect costs incurred in development of the
Company's proprietary drug delivery system. All such costs are charged to
expense when incurred.

Note 4: Stockholders' Equity

During the nine months ended September 30, 2005, the Company received net
proceeds of $43,108 ($1.022 per share) upon the exercise of 8,436 of the
Representative Unit Purchase Warrants that were issued to underwriters as part
of the 2003 public offering. This resulted in the issuance of 42,180 shares of
common stock together with a similar amount of Representative's Common Stock
Warrants. In addition, 157,180 Representative's Common Stock Warrants were
exercised ($1.28 per share) with a similar amount of common stock being issued
and receipt of net proceeds of $202,191.

The Company received a net amount of $93,600 upon the exercise of 120,000 in
stock options during the nine months ended September 30, 2005. 60,000 options
were exercised at a price of $0.71 per share and 60,000 were exercised at a
price of $0.85 per share.


                                       6.







The Company also received during the nine months ended September 30, 2005 net
proceeds of $2,780,752 upon the exercise of 1,069,526 Series B Warrants that
were issued to institutional and accredited investors as part of a private
placement in November 2004.

The following table sets forth changes in stockholders' equity during the nine
months ended September 30, 2005:



                                    Common Stock, $0.01 Par Value
                                         Issued and Outstanding                           Deficit Accumulated
                                    --------------------------------     Additional            During
                                      No. of shares        Amount       Paid in Capital     Development Stage     Total
                                      -------------        ------       ---------------   -------------------     -----


                                                                                                        
Balance at December 31, 2004           15,215,085          $152,151      $29,605,543           $(22,970,548)   $6,787,146

Issuance of common stock in
  connection with the exercise of
  2003 Representative's Unit
  Warrants                                 42,180               422           42,686                               43,108
Issuance of common stock in
  connection with the exercise of
  Representative's Common Stock
   Warrants                               157,180             1,572          200,619                              202,191
Issuance of common stock in
  connection with the exercise of
  stock options                           120,000             1,200           92,400                               93,600
Issuance of stock options as
  compensation - consultants                   -                 -             8,270                                8,270
Issuance of common stock as
  compensation to management,
  consultants, and directors for
  services                                 36,925               369          103,056                              103,425
Issuance of common stock in
  connection with the exercise of
  warrants                              1,069,526            10,695        2,770,057                            2,780,752
Net loss for nine months ended
        September 30, 2005                                                                       (2,184,164)   (2,184,164)
                                       ----------           -------       ----------             ----------     ---------
Balance at September 30, 2005          16,640,896          $166,409      $32,822,631           $(25,154,712)   $7,834,328
                                       ==========           =======       ==========             ==========     =========


Note 5: Stock Option Plan

The Company has historically accounted for its employee stock option plans in
accordance with the provisions of Accounting Principles Board ("APB") Opinion
No. 25, "Accounting for Stock Issued to Employees," and related interpretations.
As such, compensation expense is recorded on the date of grant only if the
current fair market value of the underlying stock exceeds the exercise price.

Statement of Financial Accounting Standards ("SFAS") No. 123, "Accounting for
Stock-Based Compensation" permits entities to recognize as expense over the
vesting period the fair value of all stock-based awards on the date of grant.
Alternatively, SFAS No. 123 also allows entities to continue to apply the
provisions of APB Opinion No. 25 and provide pro forma net income (loss) and pro
forma earnings (loss) per share disclosures for employee stock option grants as
if the fair-value-based method defined in SFAS No. 123 had been applied. The
Company has elected to continue to apply the provisions of APB Opinion No. 25
and provide the pro forma disclosure required by SFAS No. 123.


                                       7.








On July 7, 2005, stock options totaling 460,000 shares were granted to certain
employees and directors.

The Company uses the intrinsic value method of accounting for stock options. Had
compensation cost for the Company's employee stock options plans been determined
based on the fair value at the grant dates of awards under these plans
consistent with the methodology prescribed by SFAS No. 123, the Company's net
income (or loss) would have been adjusted to reflect the following pro forma
amounts:




                                         Three Months Ended Sept. 30,                Nine Months Ended Sept. 30,
                                     -----------------------------------      ---------------------------------------
                                          2005               2004                   2005                   2004
                                     ---------------    ----------------      -----------------     -----------------
                                                                                                    
 Net loss, as reported              $   (643,753)      $   (828,252)         $  (2,184,164)        $    (2,364,411)
 Stock-based employee
 compensation expense included
 in net loss, net of related
 tax effects                               -                   -                       -                     -
 Stock-based employee
 compensation determined under
 the fair value based method,
 net of related tax effects              (44,862)          (25,392)                (80,097)               (76,175)
                                     ===============    ================      ================       ----------------
 Pro forma net loss                $    (688,615)      $  (853,644)          $  (2,264,261)         $  (2,440,586)
                                         =======           =======            ================       ================
 Loss per share (basic and diluted):
  As reported                      $       (0.04)      $     (0.07)         $      (0.14)         $     (0. 22)
  Pro forma                                (0.04)            (0.07)                (0.14)               (0. 22)




In December 2004, the FASB issued SFAS No. 123 (Revised 2004) ("SFAS No.
123(R)"), "Share-based Payment," that will require the Company to expense costs
related to share-based payment transactions with employees. With limited
exceptions, SFAS No. 123(R) requires that the fair value of share-based payments
to employees be expensed over the period service is received and eliminates the
ability to account for these instruments under the intrinsic value method
prescribed by APB No. 25 and allowed under the original provisions of SFAS No.
123. SFAS No. 123(R) becomes mandatorily effective for the Company on January 1,
2006. SFAS No. 123(R) allows for either prospective recognition of compensation
expense or retrospective recognition, which may be back to the original issuance
of SFAS No. 123 or only to interim periods in the year of adoption. The Company
is currently evaluating these transition methods and the effects to the
financial statements.

SFAS No. 123(R) allows the use of both closed form models (e.g., Black-Scholes
Model) and open form models (e.g., lattice models) to measure the fair value of
the share-based payment as long as that model is capable of incorporating all of
the substantive characteristics unique to share-based awards. In accordance with
the transition provisions of SFAS No. 123(R), the expense attributable to an
award will be measured in accordance with the Company's measurement model at
that award's date of grant.


                                       8.








Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

     (a) Plan of Operation

                           FORWARD LOOKING STATEMENTS

This report contains forward-looking statements which are subject to certain
risks and uncertainties that can cause actual results to differ materially from
those described. Factors that may cause such differences include, but are not
limited to, uncertainties relating to our ability to successfully complete Phase
III clinical trials and secure regulatory approval of our current or future
drug-delivery system and uncertainties regarding our ability to obtain financial
and other resources for any research, development and commercialization
activities. These factors, and others, are discussed from time to time in our
filings with the Securities and Exchange Commission. You should not place undue
reliance on these forward-looking statements, which speak only as of the date
they are made. We undertake no obligation to publicly update or revise these
forward-looking statements to reflect events or circumstances after the date
they are made.

                                    OVERVIEW

Since our founding in 1988 by a team of physicians, we have been a development
stage company engaged primarily in developing and testing the Delcath system for
the treatment of liver cancer. A substantial portion of our historical expenses
have been for the development of our medical device and the clinical trials of
our product, and the pursuit of patents worldwide. We expect to continue to
incur significant losses from costs for product development, clinical studies,
securing patents, regulatory activities, manufacturing and establishment of a
sales and marketing organization without any significant revenues. A detailed
description of the cash used to fund historical operations is in the financial
statements and the notes thereto. Without an FDA-approved product and commercial
sales, we will continue to be dependent upon existing cash and the sale of
equity or debt to fund future activities. While the amount of future net losses
and time required to reach profitability are uncertain, our ability to generate
significant revenue and become profitable will depend on our success in
commercializing our device.

During 2001, Delcath initiated the clinical trial of the system for isolated
liver perfusion using the chemotherapeutic agent melphalan. A Phase I trial at
the National Cancer Institute marked an expansion in the potential labeled usage
beyond doxorubicin, the chemotherapeutic agent used in our initial clinical
trials. Enrollment of new patients in the Phase I trial was completed in 2003
and following the 2004 presentation and adoption of a Phase II clinical trial
protocol for three types of cancer in the liver, patients are being enrolled and
treated. This study involves patients with primary liver cancer, neuroendocrine
tumors and metastatic adenocarcinomas in the liver, including liver metastasis
from colorectal cancer.

During 2004, we commenced a Phase III clinical trial in Australia to proceed
with study of the Delcath drug delivery system for inoperable cancer in the
liver using doxorubicin. We are currently in discussions with additional sites
to expand this trial.


                                       9.








In May 2005, Delcath announced that it received "fast-track" status from the FDA
for treating metastatic melanoma in the liver with melphalan. The FDA's
fast-track program is designed to facilitate development and expedite the review
of new drugs or, in the case of Delcath, a new drug-device combination, having
the potential to treat illnesses which currently lack adequate therapy.

Over the next 12 months, we expect to continue to incur substantial expenses
related to the research and development of our technology, including Phase III
clinical trials using doxorubicin with the Delcath system and Phase II clinical
trials using melphalan with the Delcath system. Additional funds, when
available, will be committed to pre-clinical and clinical trials for the use of
other chemotherapy agents with the Delcath system for the treatment of liver
cancer, and for the development of additional products and components. We will
also continue efforts to qualify additional sources of the key components of our
device, in an effort to further reduce manufacturing costs and minimize
dependency on a single source of supply.

Liquidity and Capital Resources

Our available funds will be sufficient to meet our anticipated needs for working
capital and capital expenditures at least through the end of 2006. The Company
is not projecting any capital expenditures that will significantly affect the
Company's liquidity during the next 12 months.

Our future liquidity and capital requirements will depend on numerous factors,
including the progress of our research and product development programs,
including clinical studies; the timing and costs of making various United States
and foreign regulatory filings; obtaining approvals and complying with
regulations; the timing and effectiveness of product commercialization
activities, including marketing arrangements overseas; the timing and costs
involved in preparing, filing, prosecuting, defending and enforcing intellectual
property rights; and the effect of competing technological and market
developments.

The Company's future results are subject to substantial risks and uncertainties.
The Company has operated at a loss for its entire history and there can be no
assurance of its ever achieving consistent profitability. The Company believes
its capital resources are adequate to fund operations for at least the next
twelve months but anticipates that it will require additional working capital
after 2006. There can be no assurance that such working capital will be
available on acceptable terms, if at all.

During the nine months ended September 30, 2005, the Company had exercises of
previously issued warrants together with exercises of stock options. Please see
Note 4 to the September 30, 2005 Condensed Financial Statements included in Part
I of this filing and incorporated herein by reference for a complete description
of share issuances together with receipt of proceeds. We plan to use the net
proceeds to fund, in part, the Phase III clinical trial using doxorubicin and
the Phase II clinical trial at NCI using melphalan.


                                       10.






Application of Critical Accounting Policies

The Company's condensed financial statements have been prepared in accordance
with accounting principles generally accepted in the United States of America.
Certain accounting policies have a significant impact on amounts reported in the
financial statements. A summary of those significant accounting policies can be
found in Note 1 to the Company's financial statements contained in the Company's
Annual Report on Form 10-KSB for the year ended December 31, 2004 as filed with
the Securities and Exchange Commission. The Company has not adopted any
significant new accounting policies or modified the application of existing
policies during the nine months ended September 30, 2005.

     (b)  Management's Discussion and Analysis of Financial Condition and
          Results of Operations

          Not Applicable.

     (c)  Off-balance sheet arrangements

          The Company does not have any off-balance sheet arrangements.

Item 3. CONTROLS AND PROCEDURES

Based on an evaluation of the Company's disclosure controls and procedures
performed by the Company's Chief Executive Officer and its Chief Financial
Officer as of the end of the period covered by this report, the Company's Chief
Executive Officer and its Chief Financial Officer concluded that the Company's
disclosure controls and procedures have been effective.

As used herein, "disclosure controls and procedures" means controls and other
procedures of the Company that are designed to ensure that information required
to be disclosed by the Company in the reports that it files or submits under the
Securities Exchange Act is recorded, processed, summarized and reported within
the time periods specified in the rules and forms issued by the Securities and
Exchange Commission. Disclosure controls and procedures include, without
limitation, controls and procedures designed to ensure that information required
to be disclosed by the Company in the reports that it files or submits under the
Securities Exchange Act is accumulated and communicated to the Company's
management, including its principal executive officer or officers and its
principal financial officer or officers, or persons performing similar
functions, as appropriate to allow timely decisions regarding required
disclosure.

Since the date of the evaluation described above, there were no significant
changes in the Company's internal controls or in other factors that could
significantly affect these controls, and there were no corrective actions with
regard to significant deficiencies and material weaknesses.


                                       11.






                                     PART II
                                OTHER INFORMATION

Item 1. Legal Proceedings

          None

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On August 4 and August 5, 2005, the Company sold an aggregate of 1,069,526
shares of its Common Stock upon exercise of all of its then outstanding Series B
Warrants to Purchase Shares of Common Stock dated November 24, 2004 (the "Series
B Warrants"). Based on the exercise price of $2.60 for each of the Series B
Warrants, the Company received an aggregate of $2,780,752 upon such exercises.
The Company claims an exemption from registration of the offer and sale of the
shares of Common Stock issued upon exercise of the Series B Warrants under Rule
506 under the Securities Act of 1933 on the basis that each of the purchasers is
an accredited investor.

No underwriter was involved in the exercise of the Series B Warrants, and the
Company paid no underwriting discount or commission in connection therewith.

Item 3. Defaults Upon Senior Securities

          None

Item 4. Submission of Matters to a Vote of Security Holders

          None

Item 5. Other Information

     The information included in Item 2 of this report is incorporated by
reference into this Item 5.

Item 6. Exhibits


       31.1    Certification by Chief Executive Officer Pursuant to Rule 13a-14.

       31.2    Certification by Chief Financial Officer Pursuant to Rule 13a-14.

       32.1    Certification of Chief Executive Officer Pursuant to 18 U.S.C.
               Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-
               Oxley Act of 2002.

       32.2    Certification of Chief Financial Officer Pursuant to 18 U.S.C.
               Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-
               Oxley Act of 2002.


                                       12.





                                   SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the
registrant has caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.



                                           DELCATH SYSTEMS, INC.     
                                           (Registrant)


November 8, 2005                            /s/ PAUL M. FEINSTEIN
                                           --------------------------
                                           Paul M. Feinstein
                                           Chief Financial Officer (on behalf of
                                           the registrant and as the principal
                                           financial and accounting officer of
                                           the registrant)


                                       13.





                                 EXHIBIT INDEX

     Exhibit
        No.                             Description
     -------                            -----------

       31.1    Certification by Chief Executive Officer Pursuant to Rule 13a-14.

       31.2    Certification by Chief Financial Officer Pursuant to Rule 13a-14.

       32.1    Certification of Chief Executive Officer Pursuant to 18 U.S.C.
               Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-
               Oxley Act of 2002.

       32.2    Certification of Chief Financial Officer Pursuant to 18 U.S.C.
               Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-
               Oxley Act of 2002.